AD 210
Alternative Names: AD-210Latest Information Update: 08 Aug 2024
At a glance
- Originator Addpharma
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 08 Aug 2024 Discontinued - Phase-I for Hyperlipidaemia in South Korea (unspecified route) (Addpharma pipeline, August 2024)
- 08 Aug 2024 Discontinued - Phase-I for Hypertension in South Korea (unspecified route) (Addpharma pipeline, August 2024)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Hyperlipidaemia in South Korea